Even with this, you're still 20 years away from working clinical trials. These drugs are a dead end until the industry and the FDA come to a firm agreement on w

Even with this, you're still 20 years away from working clinical trials. These drugs are a dead end until the industry and the FDA come to a firm agreement on what biomarker represents Alzheimer's, and what that time scale looks like. They will never get past phase two clinical trials. 20 year clinical trials are just too expensive, and the patent window is too short. Also, there are mice with genetic engineering to approximate Alzheimer's.